Immunic is currently undervalued with a gap of 491.9% relative to the price target.
The current price is $7.28, which places Immunic in the undervalued category. The stock is considered undervalued when the price is below $38.78, and overvalued when the price exceeds $47.40.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Immunic, the fair value range lies between $38.78 and $47.40.
12 analysts cover Immunic. There is broad agreement on a positive view — 100% recommend buying. The average price target is $43.09, which gives an upside of 491.9% from the current price.
Immunic is classified as a speculative stock.
The P/B ratio is 1.4.
The Piotroski score is 2 out of 9 — weak financial health, be careful. Altman Z2 is -9.08 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 121.8% — moderate debt.
Short interest is 16.10% — very high, the market is skeptical.
In 2026, insiders at Immunic have made 19 transactions, all of which were purchases. On a net basis, insiders put $579,877 into the stock. Active insiders include Nash Duane, Tardio Jason, Neermann Joerg and others.
There has been no insider trading in the last 3 months.
Insiders have exclusively bought shares.
Across the last 19 transactions: 19 purchases and 0 sales. A net $579,877 into the stock.
Latest purchase: Nash Duane bought 20,000 shares at $0.83 each on 2025-06-13. The stock has since risen 792.8%.
Who is buying: Nash Duane, Tardio Jason, Neermann Joerg, Vitt Daniel, Whaley Glenn and others.
The table shows the last 19 reported insider transactions in Immunic. Green rows are purchases, red rows are sales. The data is based on official filings.
| Transaction date | Name | Type | Number of shares | Price per share ($) | Total amount ($) |
|---|---|---|---|---|---|
| 2025-06-13 | Nash Duane | Buy | 20,000 | 1 | 16,600 |
| 2025-06-05 | Tardio Jason | Buy | 12,512 | 1 | 9,884 |
| 2025-06-05 | Neermann Joerg | Buy | 30,000 | 1 | 22,800 |
| 2025-06-04 | Vitt Daniel | Buy | 15,000 | 1 | 11,550 |
| 2025-06-04 | Neermann Joerg | Buy | 70,000 | 1 | 53,900 |
| 2025-06-03 | Whaley Glenn | Buy | 45,000 | 1 | 31,950 |
| 2025-06-03 | Rudick Richard Alan | Buy | 143,075 | 1 | 100,153 |
| 2024-11-12 | Rudick Richard Alan | Buy | 87,300 | 1 | 100,395 |
| 2024-02-26 | Vitt Daniel | Buy | 14,000 | 1 | 18,340 |
| 2023-05-15 | Whaley Glenn | Buy | 5,000 | 2 | 8,750 |
The following insiders have bought shares in Immunic: Nash Duane, Tardio Jason, Neermann Joerg, Vitt Daniel, Whaley Glenn and others. In total, $579,877 was bought across 19 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 27, 2026.
Immunic, Inc is in a short-term downtrend. The price of $7.41 is 4.8% below the 20-day average ($7.78). Medium term, the picture is negative: the price is 33.3% below the 50-day average ($11.12). Long term, the stock is 35.4% below the 200-day average ($11.47), which signals a long-term downtrend.
Death Cross: The 50-day average (11.12) is below the 200-day average (11.47), which is a classic bearish signal for Immunic, Inc.
Immunic, Inc has an RSI of 36.4. The stock sits in the lower part of the neutral zone, which points to weak momentum without being oversold. In the current downtrend, be careful about reading this as a buying opportunity.
Daily MACD: MACD is negative (-1.008), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-1.201) by 0.193, which suggests the negative momentum is fading – a potential trend reversal could be ahead.
Weekly MACD: MACD5 is negative (-0.923), which indicates a broader bearish long-term trend. MACD5 is below the signal line (0.211) by 1.134, which confirms continued negative long-term momentum.
Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.
Trend: Negative. The price trades below SMA50 and SMA200.
MACD trend (zero line): Daily bearish (-1.008). Weekly bearish (-0.923).
MACD momentum (signal): Daily rising. Weekly falling.
RSI: 36.4 – neutral.
Technical signal: Strong Sell
The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.
Compare Immunic with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.
See all 116 stocks in the Healthcare sector